Mahana is planning a 2022 nationwide launch of its FDA-cleared prescription digital therapeutic for treating symptoms of irritable bowel syndrome.
Digital therapeutics company Mahana Therapeutics announced on 11 August it closed a $61m series B financing round.
The proceeds will be used to launch its digital therapeutic for irritable bowel syndrome, Mahana IBS (formerly Parallel), and to develop other digital therapies for chronic health conditions, the company...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
